We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Restasis Patent Redo Bid 'Inappropriate,' Fed. Circ. Told

Law360 (February 15, 2019, 6:33 PM EST) -- The row over Allergan Inc.'s controversial deal to sell patents on the dry-eye drug Restasis to a Mohawk tribe to avoid the Patent Trial and Appeal Board continues, as generic makers...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.